Blueprint Medicines Income Statement

Financials in millions USD. Fiscal year is February - January.

Millions USD. Fiscal year is Feb - Jan.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Apr '25 Apr 30, 2025	Jan '25 Jan 31, 2025	Jan '24 Jan 31, 2024	Jan '23 Jan 31, 2023
Revenue	817.24	771.88	614.34	467.73
Revenue Growth (YoY)	28.01%	25.64%	31.34%	-
Cost of Revenue	275.77	270.1	233.73	201.71
Gross Profit	541.47	501.78	380.61	266.02
Selling, General & Admin	502.37	464.28	352.78	329.01
Research & Development	273.43	261.06	201.03	158.87
Other Operating Expenses	3.66	1.71	2.58	-
Operating Expenses	779.45	727.05	556.39	487.88
Operating Income	-237.98	-225.27	-175.77	-221.86
Interest Expense	-13.42	-15.52	-16.44	-54.54
Interest & Investment Income	12.01	8.77	7.07	1.62
Other Non Operating Income (Expenses)	0.2	-0.07	1.22	1.8
EBT Excluding Unusual Items	-239.19	-232.1	-183.92	-272.97
Merger & Restructuring Charges	-	-2.5	-8.18	-
Other Unusual Items	-0.13	-2.18	1.09	-9.61
Pretax Income	-227.27	-236.78	-191.01	-282.58
Income Tax Expense	2.15	2.32	4.14	-13.06
Net Income	-229.42	-239.09	-195.15	-269.52
Preferred Dividends & Other Adjustments	107.64	120.63	45.87	13.48
Net Income to Common	-337.06	-359.73	-241.02	-283
Shares Outstanding (Basic)	56	42	33	30
Shares Outstanding (Diluted)	56	42	33	30
Shares Change (YoY)	67.13%	26.70%	9.39%	-
EPS (Basic)	-6.00	-8.53	-7.24	-9.31
EPS (Diluted)	-6.00	-8.53	-7.24	-9.31
Free Cash Flow	37.24	33.25	-68.57	-197.24
Free Cash Flow Per Share	0.66	0.79	-2.06	-6.49
Gross Margin	66.26%	65.01%	61.96%	56.88%
Operating Margin	-29.12%	-29.18%	-28.61%	-47.43%
Profit Margin	-41.24%	-46.60%	-39.23%	-60.50%
Free Cash Flow Margin	4.56%	4.31%	-11.16%	-42.17%
EBITDA	-175.64	-161.25	-106.59	-171.2
EBITDA Margin	-21.49%	-20.89%	-17.35%	-36.60%
D&A For EBITDA	62.35	64.02	69.19	50.65
EBIT	-237.98	-225.27	-175.77	-221.86
EBIT Margin	-29.12%	-29.18%	-28.61%	-47.43%
Revenue as Reported	817.24	771.88	614.34	467.73
Advertising Expenses	-	30.5	27.1	25.1

Updated Jun 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q